Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.280
+0.100 (8.47%)
At close: May 12, 2025, 4:00 PM
1.260
-0.020 (-1.54%)
After-hours: May 12, 2025, 7:40 PM EDT
Geron Market Cap
Geron has a market cap or net worth of $815.25 million as of May 12, 2025. Its market cap has decreased by -58.30% in one year.
Market Cap
815.25M
Enterprise Value
481.36M
1-Year Change
-58.30%
Ranking
Category
Stock Price
$1.28
Market Cap Chart
Since December 1, 1998, Geron's market cap has increased from $159.40M to $815.25M, an increase of 411.45%. That is a compound annual growth rate of 6.36%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 9, 2025 | 751.60M | -64.88% |
Dec 31, 2024 | 2.14B | 86.74% |
Dec 29, 2023 | 1.15B | 24.20% |
Dec 30, 2022 | 922.60M | 134.88% |
Dec 31, 2021 | 392.80M | -20.44% |
Dec 31, 2020 | 493.70M | 81.71% |
Dec 31, 2019 | 271.70M | 45.84% |
Dec 31, 2018 | 186.30M | -35.00% |
Dec 29, 2017 | 286.60M | -12.99% |
Dec 30, 2016 | 329.40M | -56.99% |
Dec 31, 2015 | 765.80M | 49.89% |
Dec 31, 2014 | 510.90M | -16.42% |
Dec 31, 2013 | 611.30M | 231.51% |
Dec 31, 2012 | 184.40M | -5.24% |
Dec 30, 2011 | 194.60M | -63.43% |
Dec 31, 2010 | 532.20M | 4.66% |
Dec 31, 2009 | 508.50M | 37.54% |
Dec 31, 2008 | 369.70M | -13.62% |
Dec 31, 2007 | 428.00M | -26.52% |
Dec 29, 2006 | 582.50M | 4.37% |
Dec 30, 2005 | 558.10M | 53.45% |
Dec 31, 2004 | 363.70M | -6.72% |
Dec 31, 2003 | 389.90M | 337.60% |
Dec 31, 2002 | 89.10M | -53.52% |
Dec 31, 2001 | 191.70M | -42.86% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 659.45B |
Johnson & Johnson | 371.06B |
UnitedHealth Group | 345.29B |
AbbVie | 326.55B |
Novo Nordisk | 297.79B |
Abbott Laboratories | 231.82B |
Novartis AG | 214.71B |
AstraZeneca | 211.14B |